Company / Current Assets
Cue Biopharma, Inc. Current Assets History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$37.0M
FY2025
5-year range
$25.1M / $77.2M
FY2021-FY2025
Trend
+47.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets returned to growth in FY2025 after 2 years of decline, reaching $37M.
Based on SEC 10-K filings.
$37M in FY2025 with a 5-year CAGR of -15.8%.
Declined from $51M to $37M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -21.7%
- 5-Year CAGR
- -15.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -15.8%, indicating a declining trend.
- In FY2025, current assets increased 47.1% year-over-year.
- Peak current assets was recorded in FY2020.
- Lowest current assets in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -7.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.0M | +47.1% |
| FY2024 | $25.1M | -51.1% |
| FY2023 | $51.5M | -33.3% |
| FY2022 | $77.2M | +12.7% |
| FY2021 | $68.5M | -21.8% |
| FY2020 | $87.5M | +43.4% |
| FY2019 | $61.0M | +50.3% |
| FY2018 | $40.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026